• 265% increase in revenue from ordinary activities to $2.9 million
• Net loss from ordinary activities after tax up 23% to $19.2 million
• Signed Philips reseller agreement and secured contracts with U.S. government and Australian radiology clinics

4DMedical, a global medical technology company, reported a strong half-year performance for the period ended 31 December 2024. Revenue from ordinary activities increased by 265% to $2.9 million, driven by the timing of the Imbio acquisition and growth in the company's General Radiology business and Clinical SaaS offerings. The net loss from ordinary activities after tax was $19.2 million, up 23% compared to the previous corresponding period, due to increased operating expenditure related to the Imbio acquisition and 4DMedical's ongoing commercialisation efforts, product development, and headcount growth. Key highlights during the period include the signing of a reseller agreement with Philips North America, securing contracts with the U.S. Department of Defense and several Australian radiology clinics, and receiving FDA clearance for the IQ-UIP™ product, an advanced AI-driven lung diagnostic tool. The company also presented clinical trial data for its CT:VQ™ technology at the Radiological Society of North America (RSNA) conference, showcasing its potential to revolutionize lung ventilation and perfusion imaging. Additionally, 4DMedical installed an XV scanner at Vanderbilt Medical Center as part of the U.S. Department of Veterans Affairs' Military Exposures Research Program.